WaferMat - Orally Disintegrating Wafer
The WaferMat technology is designed for the delivery of medication without the need for water, chewing or swallowing. The wafers are placed against the inside of the cheek to release the active ingredient directly into the systemic circulation. The Ultra-Fast-Release wafer fully dissolves in the oral cavity within 3 seconds and the Prolonged-Release wafer releases the active ingredient constantly over 8 hours.
The WaferMat Ultra-Fast-Release and Prolonged-Release wafers provide the opportunity to develop established bioactive compounds into a patient-friendly dosing system and may play a leading role in new product launches.
The WaferMat technology is based on our proprietary gel-like barrier formation and dissolution regulation which yield a unique, smooth-surfaced, macroporous architecture. Both the Ultra-Fast-Release and Prolonged-Release wafers have permeation enhancing capabilities to allow for better absorption of the active ingredient. The taste of active ingredient is masked to enhance palatability and paediatric compliance. Wafer diameter ranges between 0.5 and 1.0cm.
Patent Number: EP2306981A1
Application Number: EP2009766176A
Inventor: REDDY, Deshika | PILLAY, Viness | CHOONARA, Yahya | ADELEKE, Oluwatoyin Ayotomilola
Priority Date: 19 Jun 2008
Priority Number: EP2306981A1
Application Date: 3 Jun 2009
Publication Date: 13 Apr 2011
IPC Current: A61K000919 | A61K0031135
Assignee Applicant: University of the Witwatersrand Johannesburg,2050 Johannesburg,ZA,101055630
Title: A TRANSMUCOSAL DELIVERY SYSTEM | TRANSMUKOSALES ABGABESYSTEM | SYSTÈME D ADMINISTRATION TRANSMUQUEUSE
Usefulness: A TRANSMUCOSAL DELIVERY SYSTEM | TRANSMUKOSALES ABGABESYSTEM | SYSTÈME D ADMINISTRATION TRANSMUQUEUSE
Summary: The multi-configured, transmucosal pharmaceutical dosage form is for administration to pediatric or geriatric patients. It is used for delivering, in use, fixed-dose combinations of pharmaceutically active compounds, which are usually administered as a regimen; and delivering a pediatric drug, i.e. multivitamin, phytonutrient, mineral, and/or trace element, which are selected from Nystacid (RTM: nystatin), hyoscine, zidovudine, ascorbic acid, vitamin D, calcium, selenium, ginseng, or their pharmaceutically active isomers. The fixed-dose combination of pharmaceutically active compounds is paracetamol and tramadol. The dosage form is a porosity-enabled pharmaceutical dosage form for dermal applications as dry, flowable powders for the delivery of topical active pharmaceutical compositions. The pharmaceutically active compound(s) is selected from analgesics, sedatives, antihistamines, multivitamins, minerals, trace elements, phytonutrients, pediatric drugs, antiretroviral drugs, or their pharmaceutically active isomers. The pharmaceutically active composition is an anti-retroviral, preferably zidovudine or its pharmaceutically active isomers; and antihistamine, preferably diphenhydramine hydrochloride. Analgesic is diclofenac, aspirin, paracetamol, or their pharmaceutically active isomers. Sedative is diazepam, zolpidem, zopiclone, or their pharmaceutically active isomers. The antihistamine is loratadine, chlorpheniramine, or diphenhydramine (claimed). The dosage form is used as antiemetics, antiinflammatories, and antidiarrheals. It is useful for individuals who find swallowing tablets and/or receiving injections problematic, such as unconscious patients and patients confined to intensive care units.
Novelty: Multi-configured, transmucosal pharmaceutical dosage form for delivering e.g. multivitamin comprises multi-configured, porous, low-density, hydroscopic, mucoadhesive, pore-regulated, composite polymeric matrix having desired active compound
生物医学
医药成分
美国
